Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$14.77
+1.7%
$14.51
$6.99
$17.75
$1.75B1.672.35 million shs633,128 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$9.63
+1.2%
$10.00
$8.02
$18.80
$4.78B1.444.93 million shs2.61 million shs
Legend Biotech Co. stock logo
LEGN
Legend Biotech
$35.02
+0.9%
$34.67
$29.27
$60.87
$6.43B0.211.30 million shs372,547 shs
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$103.90
+1.2%
$97.80
$65.76
$126.89
$7.11B0.2952,244 shs321,685 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-0.55%+7.39%-7.63%+4.31%+71.55%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+0.63%+12.15%-8.51%-21.70%-28.28%
Legend Biotech Co. stock logo
LEGN
Legend Biotech
+1.23%+7.63%-1.03%-3.64%-23.40%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
+0.91%+2.07%+6.80%+12.70%+56.65%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
2.8043 of 5 stars
4.42.00.00.02.50.80.6
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
3.9139 of 5 stars
4.22.00.00.32.63.30.6
Legend Biotech Co. stock logo
LEGN
Legend Biotech
2.628 of 5 stars
3.53.00.00.02.91.70.6
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
3.9868 of 5 stars
2.51.00.04.23.52.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
2.83
Moderate Buy$18.8027.29% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.43
Hold$14.6752.38% Upside
Legend Biotech Co. stock logo
LEGN
Legend Biotech
2.92
Moderate Buy$78.82125.07% Upside
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
3.00
Buy$129.4324.58% Upside

Current Analyst Ratings Breakdown

Latest ARQT, LNTH, LEGN, and ELAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/22/2025
Legend Biotech Co. stock logo
LEGN
Legend Biotech
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$84.00 ➝ $84.00
4/16/2025
Legend Biotech Co. stock logo
LEGN
Legend Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
4/14/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $13.00
4/9/2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
4/8/2025
Legend Biotech Co. stock logo
LEGN
Legend Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
4/3/2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/3/2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
4/3/2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
3/21/2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$127.00 ➝ $122.00
3/17/2025
Legend Biotech Co. stock logo
LEGN
Legend Biotech
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$82.00 ➝ $80.00
3/12/2025
Legend Biotech Co. stock logo
LEGN
Legend Biotech
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$196.54M8.92N/AN/A$0.94 per share15.71
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.44B1.08$1.99 per share4.84$12.63 per share0.76
Legend Biotech Co. stock logo
LEGN
Legend Biotech
$627.24M10.25N/AN/A$6.88 per share5.09
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.53B4.64$8.67 per share11.98$11.91 per share8.72
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$262.14M-$1.16N/AN/AN/A-140.97%-119.11%-45.95%5/6/2025 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$1.23B$0.6724.0610.812.504.60%6.78%3.03%5/7/2025 (Estimated)
Legend Biotech Co. stock logo
LEGN
Legend Biotech
-$518.25M-$0.48N/AN/AN/A-66.92%-29.69%-19.45%5/12/2025 (Estimated)
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$326.66M$4.3717.2816.47N/A28.57%44.29%23.52%5/7/2025 (Estimated)

Latest ARQT, LNTH, LEGN, and ELAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Legend Biotech Co. stock logo
LEGN
Legend Biotech
-$0.34N/AN/AN/A$190.83 millionN/A
5/7/2025Q1 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.31N/AN/AN/A$1.17 billionN/A
5/7/2025Q1 2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.64N/AN/AN/A$377.37 millionN/A
5/6/2025Q1 2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$0.19N/AN/AN/A$64.80 millionN/A
3/11/2025Q4 2024
Legend Biotech Co. stock logo
LEGN
Legend Biotech
-$0.39$0.07+$0.46$0.07$179.00 million$186.50 million
2/27/2025Q4 2024
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.57$1.34-$0.23-$0.17$376.61 million$391.11 million
2/25/2025Q4 2024
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$0.28-$0.09+$0.19-$0.09$60.52 million$71.36 million
2/25/2025Q4 2024
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.15$0.14-$0.01-$0.02$1.01 billion$1.02 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Legend Biotech Co. stock logo
LEGN
Legend Biotech
N/AN/AN/AN/AN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
0.67
2.46
2.38
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.66
2.55
1.31
Legend Biotech Co. stock logo
LEGN
Legend Biotech
0.27
4.98
4.90
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
N/A
1.65
1.56

Institutional Ownership

CompanyInstitutional Ownership
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
N/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Legend Biotech Co. stock logo
LEGN
Legend Biotech
70.89%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
99.06%

Insider Ownership

CompanyInsider Ownership
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
9.50%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.89%
Legend Biotech Co. stock logo
LEGN
Legend Biotech
0.02%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
1.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
150118.64 million105.93 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,800496.46 million491.54 millionOptionable
Legend Biotech Co. stock logo
LEGN
Legend Biotech
1,070183.65 million182.60 millionOptionable
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
70068.48 million68.48 millionOptionable

Recent News About These Companies

Lantheus Holdings, Inc. stock logo
Lantheus (LNTH) to Release Earnings on Thursday

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arcutis Biotherapeutics stock logo

Arcutis Biotherapeutics NASDAQ:ARQT

$14.77 +0.24 (+1.65%)
As of 02:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$9.62 +0.12 (+1.21%)
As of 02:50 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Legend Biotech stock logo

Legend Biotech NASDAQ:LEGN

$35.02 +0.32 (+0.92%)
As of 02:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Lantheus stock logo

Lantheus NASDAQ:LNTH

$103.90 +1.20 (+1.16%)
As of 02:50 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.